CClinicalTrials.gg
CompletedNCT05132036EP8SHUpdated Nov 19, 2025

Lung Ultrasound Assessment of Fluid Overload in Haemodialysis Patients

An interventional study of lung ultrasound in Lung Ultrasound and Hemodialysis Complication, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Determination of the hemodialysis ultrafiltration volume is guided by the clinician's estimate of dry weight. A poor estimate of this dry weight may result in insufficient fluid depletion causing a state of volume overload, which may be associated with long-term left ventricular failure, high blood pressure and excess of mortality. The diagnosis of fluid overload in haemodialysis patient is routinely based on clinical examination which consists of cardiopulmonary auscultation and edema palpation of limb member. Clinical examination can be completed by paraclinical examinations, and bioimpedance is an objective tool that assess fluid overload state. This test provides an individualized hydration status and fluid overload based on normal extracellular volume considering body composition. Echocardiography allows an accurate assessment of blood volume status by simultaneous studying left ventricular filling pressures, systolic pulmonary artery pressure and the diameter of the inferior vena cava. Lung ultrasound analyses the B-lines defined as artefactual images resulting from contact between air in "alveoli" and water in "septa". It can estimate pulmonary congestion. The aim of the study is to evaluate the lung ultrasound using "8 sites" score accuracy for estimating fluid overload of patients before hemodialysis session.

02

Conditions studied

  • Lung Ultrasound
  • Hemodialysis Complication

Keywords

  • Lung ultrasound
  • Hemodialysis Complication
  • hemodialysis ultrafiltration volume
03

In context

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 576 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age over 18 years old
  • patients on hemodialysis for more than 3 months;
  • patients without cardiological or infectious event for at least 3 months;
  • patients having at least 2 dialysis session per week;
  • patients affiliated with a health insurance plan;
  • patients having signed an informed consent.

Exclusion criteria

Exclusion Criteria:

  • Pulmonary fibrosis or active lung disease;
  • residual diuresis over 500 mL per day;
  • body mass index (BMI) \< 21 and > 28 Kg/m²;
  • medical history of major amputation (subgonal or transfemoral);
  • pacemaker carrier;
  • patients with orthopedic prosthesis.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Interventions

  • Otherlung ultrasound

    Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the "8 sites" score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed

06

What researchers measure

Primary outcomes

  1. number of patients with fluid overload

    Fluid overloaded are determined by both tecniques : estimated fluid overload and lung ultrasound measured fluid overload

    Time frame: one day

07

Study locations

1 site
  • CHU Amiens
    Amiens, 80054, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05132036
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Nov 9, 2021
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion